William F Goins

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1314508/publications.pdf

Version: 2024-02-01

121 papers	5,456 citations	76326 40 h-index	91884 69 g-index
125 all docs	125 docs citations	125 times ranked	4074 citing authors

#	Article	IF	Citations
1	Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy. IScience, 2022, 25, 104395.	4.1	23
2	THER-02. Pediatric brain tumor cultures reveal differential susceptibility to four oncolytic viruses. Neuro-Oncology, 2022, 24, i186-i186.	1.2	0
3	Evaluation of parameters for efficient purification and long-term storage of herpes simplex virus-based vectors. Molecular Therapy - Methods and Clinical Development, 2022, 26, 132-143.	4.1	3
4	Oncolytic HSV Vectors and Anti-Tumor Immunity. Current Issues in Molecular Biology, 2021, 41, 381-468.	2.4	8
5	Varicella-zoster virus early infection but not complete replication is required for the induction of chronic hypersensitivity in rat models of postherpetic neuralgia. PLoS Pathogens, 2021, 17, e1009689.	4.7	8
6	Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment. Molecular Therapy - Oncolytics, 2021, 22, 444-453.	4.4	1
7	EXTH-61. MODULATION OF THE IL-27 RECEPTOR SIGNALING PATHWAY IN GLIOBLASTOMA AND ONCOLYTIC VIROTHERAPY. Neuro-Oncology, 2021, 23, vi177-vi177.	1.2	0
8	A Guide to Preclinical Models of Zoster-Associated Pain and Postherpetic Neuralgia. Current Topics in Microbiology and Immunology, 2021, , 189-221.	1.1	2
9	Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFRÎ±1 for Specific Infection of Breast Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 8815.	4.1	7
10	Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses. Scientific Reports, 2020, 10, 5095.	3.3	28
11	Protocol Optimization for the Production of the Non-Cytotoxic JÎ”NI5 HSV Vector Deficient in Expression of Immediately Early Genes. Molecular Therapy - Methods and Clinical Development, 2020, 17, 612-621.	4.1	5
12	Engineering HSV-1 Vectors for Gene Therapy. Methods in Molecular Biology, 2020, 2060, 73-90.	0.9	17
13	GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Molecular Therapy - Oncolytics, 2019, 15, 214-222.	4.4	28
14	The effect of herpes simplex virus vectorâ€mediated gene therapy of protein phosphatase 1Î± on bladder overactivity and nociception. Neurourology and Urodynamics, 2019, 38, 582-590.	1.5	1
15	Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. Clinical Cancer Research, 2019, 25, 290-299.	7.0	88
16	Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. Clinical Cancer Research, 2018, 24, 2574-2584.	7.0	40
17	Effects of herpes simplex virus vectors encoding poreless TRPV1 or protein phosphatase 1Î± in a rat cystitis model induced by hydrogen peroxide. Gene Therapy, 2018, 25, 20-26.	4.5	1
18	Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Molecular Therapy - Oncolytics, 2018, 11, 62-74.	4.4	41

#	Article	IF	Citations
19	Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System. Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 1	2.5	40
20	Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes. Molecular Therapy - Methods and Clinical Development, 2017, 6, 79-90.	4.1	14
21	MnSOD mediated by HSV vectors in the periaqueductal gray suppresses morphine withdrawal in rats. Gene Therapy, 2017, 24, 314-324.	4.5	10
22	Morphological changes in different populations of bladder afferent neurons detected by herpes simplex virus (HSV) vectors with cell-type-specific promoters in mice with spinal cord injury. Neuroscience, 2017, 364, 190-201.	2.3	17
23	An HSV-based library screen identifies PP1Î± as a negative TRPV1 regulator with analgesic activity in models of pain. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16040.	4.1	9
24	Retargeting of herpes simplex virus (HSV) vectors. Current Opinion in Virology, 2016, 21, 93-101.	5.4	24
25	Current Gene Therapy using Viral Vectors for Chronic Pain. Molecular Pain, 2015, 11, s12990-015-0018.	2.1	55
26	Interferon-stimulated Gene 15 (ISG15) and ISG15-linked Proteins Can Associate with Members of the Selective Autophagic Process, Histone Deacetylase 6 (HDAC6) and SQSTM1/p62. Journal of Biological Chemistry, 2015, 290, 1485-1495.	3.4	85
27	Gene Therapy for Neurological Diseases. , 2015, , 129-146.		0
28	Herpes Simplex Virus Vector-Mediated Gene Delivery of Poreless TRPV1 Channels Reduces Bladder Overactivity and Nociception in Rats. Human Gene Therapy, 2015, 26, 734-742.	2.7	18
29	Neuronal changes induced by Varicella Zoster Virus in a rat model of postherpetic neuralgia. Virology, 2015, 482, 167-180.	2.4	28
30	Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1632-41.	7.1	51
31	Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV. Molecular Therapy, 2015, 23, 99-107.	8.2	69
32	Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. Journal of Clinical Investigation, 2015, 125, 4269-4280.	8.2	57
33	Relief of pain induced by varicella-zoster virus in a rat model of post-herpetic neuralgia using a herpes simplex virus vector expressing enkephalin. Gene Therapy, 2014, 21, 694-702.	4.5	24
34	Gene Therapy: Charting a Future Courseâ€"Summary of a National Institutes of Health Workshop, April 12, 2013. Human Gene Therapy, 2014, 25, 488-497.	2.7	12
35	Engineering HSV-1 Vectors for Gene Therapy. Methods in Molecular Biology, 2014, 1144, 63-79.	0.9	51
36	Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. Molecular Therapy - Oncolytics, 2014, 1, 14010.	4.4	33

#	Article	IF	Citations
37	Effects of Herpes Simplex Virus Vectorâ€“Mediated Enkephalin Gene Therapy on Bladder Overactivity and Nociception. Human Gene Therapy, 2013, 24, 170-180.	2.7	18
38	Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV. Gene Therapy, 2013, 20, 761-769.	4.5	12
39	Effective Treatment of an Orthotopic Xenograft Model of Human Glioblastoma Using an EGFR-retargeted Oncolytic Herpes Simplex Virus. Molecular Therapy, 2013, 21, 561-569.	8.2	94
40	VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells. Molecular Therapy, 2013, 21, 1014-1023.	8.2	34
41	Progress in gene therapy for neurological disorders. Nature Reviews Neurology, 2013, 9, 277-291.	10.1	202
42	Herpes Simplex Virus Vector Mediated Gene Therapy of Tumor Necrosis Factor-Î± Blockade for Bladder Overactivity and Nociception in Rats. Journal of Urology, 2013, 189, 366-373.	0.4	24
43	Effect of herpes simplex virus vector-mediated interleukin-4 gene therapy on bladder overactivity and nociception. Gene Therapy, 2013, 20, 194-200.	4.5	16
44	Gene therapy for the treatment of chronic peripheral nervous system pain. Neurobiology of Disease, 2012, 48, 255-270.	4.4	51
45	Generation of Replication-Competent and -Defective HSV Vectors. Cold Spring Harbor Protocols, 2011, 2011, pdb.prot5615-pdb.prot5615.	0.3	7
46	Varicella zoster virus-induced pain and post-herpetic neuralgia in the human host and in rodent animal models. Journal of NeuroVirology, 2011, 17, 590-599.	2.1	33
47	HSV Delivery of a Ligand-regulated Endogenous Ion Channel Gene to Sensory Neurons Results in Pain Control Following Channel Activation. Molecular Therapy, 2011, 19, 500-506.	8.2	24
48	Equine herpesvirus type 1 (EHV-1) utilizes microtubules, dynein, and ROCK1 to productively infect cells. Veterinary Microbiology, 2010, 141, 12-21.	1.9	35
49	A Double Mutation in Glycoprotein gB Compensates for Ineffective gD-Dependent Initiation of Herpes Simplex Virus Type 1 Infection. Journal of Virology, 2010, 84, 12200-12209.	3.4	48
50	Herpes Simplex Virus Vectors. , 2010, , 69-85.		0
51	Suppression of Detrusor-Sphincter Dyssynergia by Herpes Simplex Virus Vector Mediated Gene Delivery of Glutamic Acid Decarboxylase in Spinal Cord Injured Rats. Journal of Urology, 2010, 184, 1204-1210.	0.4	27
52	Generation of Herpesvirus Entry Mediator (HVEM)-Restricted Herpes Simplex Virus Type 1 Mutant Viruses: Resistance of HVEM-Expressing Cells and Identification of Mutations That Rescue Nectin-1 Recognition. Journal of Virology, 2009, 83, 2951-2961.	3.4	31
53	Gene Therapy for Bladder Overactivity and Nociception with Herpes Simplex Virus Vectors Expressing Preproenkephalin. Human Gene Therapy, 2009, 20, 63-71.	2.7	38
54	Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain. Gene Therapy, 2009, 16, 558-569.	4.5	17

#	Article	IF	Citations
55	Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats. Gene Therapy, 2009, 16, 660-668.	4.5	40
56	Gene Therapy for Neurogenic Erectile Dysfunction. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S44.	1.3	0
57	Construction and Production of Recombinant Herpes Simplex Virus Vectors. Methods in Molecular Biology, 2008, 433, 97-103.	0.9	12
58	Equine Herpesvirus 1 Enters Cells by Two Different Pathways, and Infection Requires the Activation of the Cellular Kinase ROCK1. Journal of Virology, 2007, 81, 10879-10889.	3.4	62
59	Gene therapy applications for the treatment of neuropathic pain. Expert Review of Neurotherapeutics, 2007, 7, 487-506.	2.8	20
60	Herpes simplex virus vector-mediated delivery of glial cell line-derived neurotrophic factor rescues erectile dysfunction following cavernous nerve injury. Gene Therapy, 2007, 14, 1344-1352.	4.5	38
61	Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection. Virology, 2007, 360, 477-491.	2.4	14
62	Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-Î² peptide in vivo. Gene Therapy, 2006, 13, 1068-1079.	4.5	94
63	Soluble V Domain of Nectin-1/HveC Enables Entry of Herpes Simplex Virus Type 1 (HSV-1) into HSV-Resistant Cells by Binding to Viral Glycoprotein D. Journal of Virology, 2006, 80, 138-148.	3.4	43
64	A new transgene reporter for in vivo magnetic resonance imaging. Nature Medicine, 2005, 11, 450-454.	30.7	419
65	HSV vector-mediated transduction and GDNF secretion from adipose cells. Gene Therapy, 2005, 12, 48-58.	4.5	13
66	HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Therapy, 2005, 12, 891-901.	4.5	87
67	Herpes Simplex Virus Targeting to the EGF Receptor by a gD-Specific Soluble Bridging Molecule. Molecular Therapy, 2005, 11, 617-626.	8.2	44
68	Equine Herpesvirus 1 Utilizes a Novel Herpesvirus Entry Receptor. Journal of Virology, 2005, 79, 3169-3173.	3.4	25
69	IMPROVEMENT IN ERECTILE DYSFUNCTION AFTER NEUROTROPHIC FACTOR GENE THERAPY IN DIABETIC RATS. Journal of Urology, 2005, 173, 1820-1824.	0.4	51
70	Delivery Using Herpes Simplex Virus: An Overview. , 2004, 246, 257-300.		35
71	Delivery of Herpes Simplex Virus-Based Vectors to Stem Cells. , 2004, 246, 339-352.		1
72	Gene Transfer to Glial Tumors Using Herpes Simplex Virus. , 2004, 246, 323-338.		7

#	Article	IF	Citations
73	Immobilized Cobalt Affinity Chromatography Provides a Novel, Efficient Method for Herpes Simplex Virus Type 1 Gene Vector Purification. Journal of Virology, 2004, 78, 8994-9006.	3.4	38
74	Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain, 2004, 127, 929-939.	7.6	54
75	Gene Therapy Using Replication-Defective Herpes Simplex Virus Vectors Expressing Nerve Growth Factor in a Rat Model of Diabetic Cystopathy. Diabetes, 2004, 53, 2723-2730.	0.6	92
76	Protective effect of HSV-mediated gene transfer of nerve growth factor in pyridoxine neuropathy demonstrates functional activity of trkA receptors in large sensory neurons of adult animals. European Journal of Neuroscience, 2003, 17, 732-740.	2.6	39
77	Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain, 2003, 102, 135-142.	4.2	126
78	Virus-based vectors for gene expression in mammalian cells: Herpes simplex virus. New Comprehensive Biochemistry, 2003, 38, 27-54.	0.1	1
79	Redirecting the Tropism of HSV-1 for Gene Therapy Applications. , 2003, , 377-403.		0
80	Development of Replication-Defective Herpes Simplex Virus Vectors. , 2002, 69, 481-507.		15
81	Herpes Simplex-Mediated Gene Transfer of Nerve Growth Factor Protects Against Peripheral Neuropathy in Streptozotocin-Induced Diabetes in the Mouse. Diabetes, 2002, 51, 2227-2232.	0.6	129
82	Construction of Replicationâ€Defective Herpes Simplex Virus Vectors. Current Protocols in Human Genetics, 2002, 33, Unit 12.11.	3.5	4
83	Gene Transfer to Muscle and Spinal Cord Using Herpes Simplex Virus-Based Vectors. , 2002, , 179-200.		2
84	Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Annals of Neurology, 2002, 52, 662-665.	5.3	109
85	Effect of genetic background and culture conditions on the production of herpesvirus-based gene therapy vectors. Biotechnology and Bioengineering, 2002, 77, 685-692.	3.3	42
86	Effect of temperature, medium composition, and cell passage on production of herpes-based viral vectors. Biotechnology and Bioengineering, 2002, 79, 112-119.	3.3	25
87	Replication-defective genomic herpes simplex vectors: design and production. Current Opinion in Biotechnology, 2002, 13, 424-428.	6.6	45
88	Evaluation of Infection Parameters in the Production of Replication-Defective HSV-1 Viral Vectors. Biotechnology Progress, 2002, 18, 476-482.	2.6	25
89	HERPES SIMPLEX VIRUS MEDIATED NERVE GROWTH FACTOR EXPRESSION IN BLADDER AND AFFERENT NEURONS: POTENTIAL TREATMENT FOR DIABETIC BLADDER DYSFUNCTION. Journal of Urology, 2001, 165, 1748-1754.	0.4	96
90	Multiple Applications For Replication-Defective Herpes Simplex Virus Vectors. Stem Cells, 2001, 19, 358-377.	3.2	69

#	Article	IF	Citations
91	Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Therapy, 2001, 8, 551-556.	4.5	160
92	Targeting gene expression using HSV vectors. Advanced Drug Delivery Reviews, 2001, 53, 155-170.	13.7	23
93	Herpesvirus-Mediated Systemic Delivery of Nerve Growth Factor. Molecular Therapy, 2001, 3, 61-69.	8.2	41
94	HERPES SIMPLEX VIRUS MEDIATED NERVE GROWTH FACTOR EXPRESSION IN BLADDER AND AFFERENT NEURONS: POTENTIAL TREATMENT FOR DIABETIC BLADDER DYSFUNCTION. Journal of Urology, 2001, , 1748-1754.	0.4	6
95	Effect of Protease Inhibitors on Yield of HSV-1-Based Viral Vectors. Biotechnology Progress, 2000, 16, 493-496.	2.6	13
96	Herpes Simplex Virus-Enhanced Cationic Lipid/DNA-Mediated Transfection. BioTechniques, 2000, 29, 810-814.	1.8	3
97	Connexin 43-Enhanced Suicide Gene Therapy Using Herpesviral Vectors. Molecular Therapy, 2000, 1, 71-81.	8.2	87
98	Pseudotyping of Glycoprotein D-Deficient Herpes Simplex Virus Type 1 with Vesicular Stomatitis Virus Glycoprotein G Enables Mutant Virus Attachment and Entry. Journal of Virology, 2000, 74, 2481-2487.	3.4	55
99	Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle. Journal of Gene Medicine, 1999, 1, 280-289.	2.8	69
100	Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3211-3216.	7.1	215
101	Herpes Simplex Virus Type 1 Vector-Mediated Expression of Nerve Growth Factor Protects Dorsal Root Ganglion Neurons from Peroxide Toxicity. Journal of Virology, 1999, 73, 519-532.	3.4	90
102	Genetic Studies Exposing the Splicing Events Involved in Herpes Simplex Virus Type 1 Latency-Associated Transcript Production during Lytic and Latent Infection. Journal of Virology, 1999, 73, 3866-3876.	3.4	23
103	Development of Replication-Defective Herpes Simplex Virus Vectors. , 1997, 7, 79-102.		21
104	Engineering Herpes Simplex. Advances in Pharmacology, 1997, 40, 103-136b.	2.0	26
105	Development of an HSV-Based Vector for the Treatment of Parkinson's Disease. Experimental Neurology, 1997, 144, 103-112.	4.1	18
106	Progress in development of herpes simplex virus gene vectors for treatment of rheumatoid arthritis. Advanced Drug Delivery Reviews, 1997, 27, 41-57.	13.7	29
107	Replication-defective herpes simplex virus vectors for gene transfer in vivo.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11319-11320.	7.1	163
108	Gene Transfer to Neurons Using Herpes Simplex Virus-Based Vectors. Annual Review of Neuroscience, 1996, 19, 265-287.	10.7	166

#	Article	IF	Citations
109	[8] Site-specific integration of multigenic shuttle plasmids into the herpes simplex virus type 1 genome using a cell-free cre-lox recombination system. Methods in Molecular Genetics, 1995, 7, 114-130.	0.6	11
110	HSV as a gene transfer vector for the nervous system. Molecular Biotechnology, 1995, 4, 87-99.	2.4	26
111	Herpes Simplex Virus as a Gene-Delivery Vector for the Central Nervous System. , 1995, , 1-23.		10
112	Two herpes simplex virus type 1 latency-active promoters differ in their contributions to latency-associated transcript expression during lytic and latent infections. Journal of Virology, 1995, 69, 7899-7908.	3.4	105
113	Gene transfer to brain using herpes simplex virus vectors. Annals of Neurology, 1994, 35, S28-S34.	5.3	61
114	Development of Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System. , 1994, , 281-302.		6
115	Neurovirulence of Herpes Simplex Virus Type 1 Accessory Gene Mutants. Frontiers of Virology, 1994, , 222-237.	0.6	4
116	A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. Journal of Virology, 1994, 68, 2239-2252.	3.4	186
117	Resistance of herpes simplex virus type 2 to neomycin maps to the N-terminal portion of glycoprotein C. Journal of Virology, 1993, 67, 2434-2441.	3.4	22
118	In Vivo Expression of Î²-Galactosidase in Hippocampal Neurons by HSV-Mediated Gene Transfer. Human Gene Therapy, 1992, 3, 11-19.	2.7	218
119	Genetic analysis of type-specific antigenic determinants of herpes simplex virus glycoprotein C. Journal of Virology, 1992, 66, 4864-4873.	3.4	24
120	Oligomer formation of the gB glycoprotein of herpes simplex virus type 1. Journal of Virology, 1991, 65, 4275-4283.	3.4	41
121	Advances in Engineering HSV Vectors for Gene Transfer to the Nervous System. , 0, , 127-163.		1